Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1470
Shown on this page
12
Current sort
Recently updated
Campus scope
Emory University (Winship Cancer Institute), Atlanta, GA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Emory University (Winship Cancer Institute), Atlanta, GA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 841–852 of 1,470 matching trials with a site at Emory University (Winship Cancer Institute), Atlanta, GA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
Site status not listed — check the official record
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting No phase listed Observational

A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

NCT05197036
Site status not listed — check the official record
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions
Total Knee Arthroplasty
Procedure
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Novi, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 4 Interventional

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

NCT05180773
Status at this site: Recruiting
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Postpartum
Interventions
Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
Drug
Lead sponsor
Dennis M. McNamara, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 2 Interventional

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

NCT07108387
Status at this site: Recruiting
View directory record Official record
Conditions
Giant Cell Arteritis (GCA)
Interventions
Tocilizumab, Discontinue Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Not applicable Interventional

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT06526858
Status at this site: Recruiting
View directory record Official record
Conditions
Resistant Hypertension
Interventions
HyperQureTM Renal Denervation (RDN) System:
Device
Lead sponsor
DeepQure Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Orange, California • Stanford, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608
Status at this site: Recruiting
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 1 mg/kg every two weeks
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 1 Interventional

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06823167
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Malignancies, Hematologic Malignancies
Interventions
IM-1021
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Active, not recruiting No phase listed Observational

INSPIRE Pipeline™ Shield Post Approval Study

NCT05071963
Site status not listed — check the official record
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Treatment of Intracranial Aneurysms
Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
22 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • New Haven, Connecticut • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 1 Interventional

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

NCT06638307
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
MEN2312, Elacestrant
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
37
States / cities
Springdale, Arkansas • Duarte, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
Status at this site: Recruiting
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Thrive With Type 1 Diabetes 2026

NCT07522866
Status at this site: Recruiting
View directory record Official record
Conditions
Type1diabetes
Interventions
TranS-C Intervention Arm, Attention Control Enhanced Usual Care (EUC) Arm
Behavioral
Lead sponsor
Emory University
Other
Eligibility
31 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 9, 2026, 1:37 PM EST
Recruiting Phase 1 Interventional

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

NCT07006688
Status at this site: Recruiting
View directory record Official record
Conditions
IDH1-Mutated Malignancies
Interventions
Ivosidenib Oral Tablet
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 9, 2026, 1:37 PM EST

About this Emory University (Winship Cancer Institute) institution page

What this page lists
ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.